Exogenous soluble human ␣3 noncollagenous (NC1) domain of collagen IV inhibits angiogenesis and tumor growth. These biological functions are attributed to the binding of ␣3NC1 to integrin ␣v3. However, in some tumor cells that express integrin ␣v3, the ␣3NC1 domain does not inhibit proliferation, suggesting that integrin ␣v3 expression is not sufficient to mediate the anti-tumorigenic activity of this domain. Therefore, in the present study, we searched for novel binding receptors for the soluble ␣3NC1 domain in cells lacking ␣v3 integrin. In these cells, soluble ␣3NC1 bound integrin ␣31; however, unlike ␣v3, ␣31 integrin did not mediate cell adhesion to immobilized ␣3NC1 domain. Interestingly, in cells lacking integrin ␣31, adhesion to the ␣3NC1 domain was enhanced due to activation of integrin ␣v3. These findings indicate that integrin ␣31 is a receptor for the ␣3NC1 domain and transdominantly inhibits integrin ␣v3 activation. Thus integrin ␣31, in conjunction with integrin ␣v3, modulates cellular responses to the ␣3NC1 domain, which may be pivotal in the mechanism underpinning its anti-angiogenic and anti-tumorigenic activities.
The NC14 domain of certain ␣-chains of type IV collagen display activity as inhibitors of angiogenesis and tumor growth. The capacity of the exogenous ␣1NC1 and ␣2NC1 domains to disrupt basement membrane assembly, blocking tissue development in vivo, was first described in Hydra vulgaris (1). Subsequent to these observations, we were the first to demonstrate that the recombinant ␣2NC1 and ␣3NC1 domains of human collagen IV potently inhibited tumor growth and angiogenesis by binding to endothelial cells in an integrin ␣v3-dependent manner (2). Since these initial observations, NC1 domains of different collagen IV chains have emerged as a new class of anti-angiogenic and anti-tumorigenic molecules (3, 4). These domains exert their effects by direct binding to tumor and endothelial cells where they induce apoptosis and/or inhibit cell proliferation. The mechanism of action of the NC1 domains is attributed to their interactions with integrins, transmembrane receptors for extracellular matrix components (5). NC1 domains bind to distinct integrins, for example ␣1NC1 to integrin ␣11 (3), ␣2NC1 to integrins ␣11, ␣v3, and ␣v5 (6, 7), and ␣3NC1 to integrins ␣v3 and ␣v5 (2, 4, 8).The ␣3NC1 domain is the best characterized of these domains and its anti-tumorigenic effects are predominantly ascribed to its potent anti-angiogenic properties. Endothelial cells adhere to this domain in an integrin ␣v3-dependent manner (2, 8). Furthermore, integrin ␣v3 is thought to mediate ␣3NC1-dependent inhibition of endothelial cell proliferation (9). In addition to its anti-angiogenic effects, the ␣3NC1 domain or peptides derived from its C-terminal third also inhibit melanoma cell growth both in vivo and in vitro in an integrin ␣v3-dependent manner (10 -13). Interestingly, the tumor cell inhibition is cell type specific, as the ␣3NC1 domain does not inhibit the proliferation of PC-3 prosta...